• U.S. FDA approval of Talicia® for the treatment of Helicobacter pylori infection in adults
• Strategic partnership with Cosmo Pharmaceuticals, including investment of $36.3 million and exclusive rights to
commercialize Aemcolo® in the U.S. for travelers’ diarrhea
• Accelerating expansion of commercial sales team in the U.S. ahead of planned launches of Aemcolo® and Talicia® in
Q4/2019 and Q1/2020, respectively
• Debt-free balance sheet with approximately $59 million as of October 22, 2019 following the investment by Cosmo
Pharmaceuticals.
Technically, as long it above 6.1, target it 6.7 and 7 .
Good-luck
Not for a suggestion.
• Strategic partnership with Cosmo Pharmaceuticals, including investment of $36.3 million and exclusive rights to
commercialize Aemcolo® in the U.S. for travelers’ diarrhea
• Accelerating expansion of commercial sales team in the U.S. ahead of planned launches of Aemcolo® and Talicia® in
Q4/2019 and Q1/2020, respectively
• Debt-free balance sheet with approximately $59 million as of October 22, 2019 following the investment by Cosmo
Pharmaceuticals.
Technically, as long it above 6.1, target it 6.7 and 7 .
Good-luck
Not for a suggestion.
Feragatname
Bilgiler ve yayınlar, TradingView tarafından sağlanan veya onaylanan finansal, yatırım, işlem veya diğer türden tavsiye veya tavsiyeler anlamına gelmez ve teşkil etmez. Kullanım Şartları'nda daha fazlasını okuyun.
Feragatname
Bilgiler ve yayınlar, TradingView tarafından sağlanan veya onaylanan finansal, yatırım, işlem veya diğer türden tavsiye veya tavsiyeler anlamına gelmez ve teşkil etmez. Kullanım Şartları'nda daha fazlasını okuyun.